HomeDiabetesTolerx And GlaxoSmithKline Announce Phase 3 Defend-1 Study Of Otelixizumab In Type 1 Diabetes Did Not Meet Its Primary Endpoint

Comments

Tolerx And GlaxoSmithKline Announce Phase 3 Defend-1 Study Of Otelixizumab In Type 1 Diabetes Did Not Meet Its Primary Endpoint — No Comments

Leave a Reply

Your email address will not be published. Required fields are marked *